A Study of LY3361237 in Participants With Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-27

Study Completion Date

2022-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3471851 in Participants With Psoriasis

NCT04119557

Psoriasis

COMPLETED PHASE1

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

NCT03418493

Psoriasis

COMPLETED PHASE1

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06176768

Plaque Psoriasis

COMPLETED PHASE2

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

NCT04152382

Psoriasis

TERMINATED PHASE1

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06602219

Plaque Psoriasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3361237

LY3361237 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY3361237

Intervention Type DRUG

Administered SC

Placebo

Placebo administered SC.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3361237

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have chronic plaque psoriasis for at least 6 months
* Be willing and able to undergo skin biopsies
* Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²)
* Female participants must agree to use birth control during the study

Exclusion Criteria

* Have had certain types of infection within the last six months
* Have a clinically significant active infection, or recent acute active infection within the last 30 days
* Have other serious or unstable illnesses
* Have a history of organ or bone marrow transplant
* Have received any live vaccine within the last 4 weeks prior to screening
* Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1
* Have received topical psoriasis treatment within 14 days prior to study day 1
* Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No